Form 4: AtriCure CSO Sells 5,000 Shares in Planned Transaction

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, sold 5,000 shares of common stock for approximately $149,150 through a pre-arranged trading plan.

Summary

• Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc. (ATRC), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of AtriCure common stock.
• The shares were sold on March 12, 2026, at a weighted average price of $29.83 per share.
• The total value of the shares sold was approximately $149,150.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan.
• Following this transaction, Mr. Doraiswamy directly beneficially owns 96,875 shares of AtriCure common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which typically mitigates negative sentiment as it suggests a planned financial management action rather than a reaction to new, adverse company-specific information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common occurrences in the market. While this specific transaction is a sale by a Chief Scientific Officer, it was conducted under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not necessarily indicative of a change in the insider's view of the company's immediate prospects. Such planned sales are a routine part of executive compensation and personal financial management.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a standard practice across industries for executives to diversify holdings and manage liquidity without concerns of trading on material non-public information. For example, similar planned sales are frequently observed at medical device companies like Medtronic (MDT) or Boston Scientific (BSX) where executives periodically sell shares.

Stakeholder Impact

• Shareholders: The sale reduces the direct equity stake of a key executive, which could be interpreted in various ways, though the 10b5-1 plan context suggests it's a routine event.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale executed under a Rule 10b5-1 plan. Such planned transactions are generally not considered a strong indicator for immediate stock price movements or a change in the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate as this specific event does not provide new material information to alter an existing investment thesis.

Keywords

AtriCure, ATRC, Insider Trading, Form 4, Stock Sale, Chief Scientific Officer, Vinayak Doraiswamy, Rule 10b5-1